StemCells, Inc. reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SCA human neural stem cell platform in dry age-related macular degeneration yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research in Vancouver, Canada.
http://ift.tt/1qw7xVZ
http://ift.tt/1qw7xVZ
No comments:
Post a Comment